With the exception of ribozymes, nucleic acid molecules within cells primarily serve as storage of genetic information due to its ability to form complementary base pairs, which allows for high-fidelity copying and transfer
of genetic information. In contrast, nucleic acid molecules are more
limited in their catalytic ability, in comparison to protein enzymes, to
just three types of interactions: hydrogen bonding, pi stacking, and metal-ion coordination. This is due to the limited number of functional groups of the nucleic acid monomers: while proteins are built from up to twenty different amino acids with various functional groups, nucleic acids are built from just four chemically similar nucleobases. In addition, DNA lacks the 2'-hydroxyl group found in RNA which limits the catalytic competency of deoxyribozymes even in comparison to ribozymes.
In addition to the inherent inferiority of DNA catalytic activity, the apparent lack of naturally occurring deoxyribozymes may also be due to the primarily double-stranded conformation of DNA in biological systems which would limit its physical flexibility and ability to form tertiary structures, and so would drastically limit the ability of double-stranded DNA to act as a catalyst; though there are a few known instances of biological single-stranded DNA such as multicopy single-stranded DNA (msDNA), certain viral genomes, and the replication fork formed during DNA replication. Further structural differences between DNA and RNA may also play a role in the lack of biological deoxyribozymes, such as the additional methyl group of the DNA base thymidine compared to the RNA base uracil or the tendency of DNA to adopt the B-form helix while RNA tends to adopt the A-form helix. However, it has also been shown that DNA can form structures that RNA cannot, which suggests that, though there are differences in structures that each can form, neither is inherently more or less catalytic due to their possible structural motifs.
In addition to the inherent inferiority of DNA catalytic activity, the apparent lack of naturally occurring deoxyribozymes may also be due to the primarily double-stranded conformation of DNA in biological systems which would limit its physical flexibility and ability to form tertiary structures, and so would drastically limit the ability of double-stranded DNA to act as a catalyst; though there are a few known instances of biological single-stranded DNA such as multicopy single-stranded DNA (msDNA), certain viral genomes, and the replication fork formed during DNA replication. Further structural differences between DNA and RNA may also play a role in the lack of biological deoxyribozymes, such as the additional methyl group of the DNA base thymidine compared to the RNA base uracil or the tendency of DNA to adopt the B-form helix while RNA tends to adopt the A-form helix. However, it has also been shown that DNA can form structures that RNA cannot, which suggests that, though there are differences in structures that each can form, neither is inherently more or less catalytic due to their possible structural motifs.
Types
Ribonucleases
The most abundant class of deoxyribozymes are ribonucleases, which catalyze the cleavage of a ribonucleotide phosphodiester bond through a transesterification reaction, forming a 2'3'-cyclic phosphate terminus and a 5'-hydroxyl terminus.
Ribonuclease deoxyribozymes typically undergo selection as long,
single-stranded oligonucleotides which contain a single ribonucleotide
base to act as the cleavage site. Once sequenced, this single-stranded
"cis"-form of the deoxyribozyme can be converted to the two-stranded
"trans"-form by separating the substrate domain (containing the
ribonucleotide cleavage site) and the enzyme domain (containing the
catalytic core) into separate strands which can hybridize through two flanking arms consisting of complementary base pairs.
The first known deoxyribozyme was a ribonuclease, discovered in 1994 by Ronald Breaker while a postdoctoral fellow in the laboratory of Gerald Joyce at the Scripps Research Institute.
This deoxyribozyme, later named GR-5,
catalyzes the Pb2+-dependent
cleavage of a single ribonucleotide phosphoester at a rate that is more
than 100-fold compared to the uncatalyzed reaction. Subsequently, additional RNA-cleaving deoxyribozymes that incorporate different metal cofactors were developed, including the Mg2+-dependent E2 deoxyribozyme
and the Ca2+-dependent Mg5 deoxyribozyme.
These first deoxyribozymes were unable to catalyze a full RNA substrate
strand, but by incorporating the full RNA substrate strand into the
selection process, deoxyribozymes which functioned with substrates
consisting of either full RNA or full DNA with a single RNA base were
both able to be utilized.
The first of these more versatile deoxyribozymes, 8-17 and 10-23, are
currently the most widely studied deoxyribozymes. In fact, many
subsequently discovered deoxyribozymes were found to contain the same
catalytic core motif as 8-17, including the previously discovered Mg5,
suggesting that this motif represents the "simplest solution for the RNA
cleavage problem".
The 10-23 DNAzyme contains a 15-nucleotide catalytic core that is
flanked by two substrate recognition domains. This DNAzyme cleaves
complementary RNAs efficiently in a sequence specific manner between an
unpaired purine and a paired pyrimidine. DNAzymes targeting AU or GU vs.
GC or AC are more effective. Furthermore, the RNA cleavage rates have
been shown to increase after the introduction of intercalators or the
substitution of deoxyguanine with deoxyinosine at the junction of the
catalytic loop. Specifically, the addition of 2’-O-methyl modifications
to the catalytic proved to significantly increase the cleavage rate both
in vitro and in vivo.
Other notable deoxyribozyme ribonucleases are those that are highly
selective for a certain cofactor. Among this group are the metal
selective deoxyribozymes such as Pb2+-specific 17E,
UO22+-specific 39E,
and Na+-specific A43. First crystal structure of a DNAzyme was reported in 2016. 10-23 core based DNAzymes and the respective MNAzymes that catalyse reactions at ambient temperatures were described in 2018 and open doors for use of these nucleic acid based enzymes for many other applications without the need for heating.
This link and this link
describe the DNA molecule
5'-GGAGAACGCGAGGCAAGGCTGGGAGAAATGTGGATCACGATT-3' , which acts as a
deoxyribozyme that uses light to repair a thymine dimer, using serotonin as cofactor.
RNA ligases
Of particular interest are DNA ligases. These molecules have demonstrated remarkable chemoselectivity in RNA branching reactions. Although each repeating unit in a RNA strand owns a free hydroxyl group, the DNA ligase takes just one of them as a branching starting point. This cannot be done with traditional organic chemistry.
Other reactions
Many other deoxyribozymes have since been developed that catalyze DNA phosphorylation, DNA adenylation, DNA deglycosylation, porphyrin metalation, thymine dimer photoreversion
and DNA cleavage.
Methods
in vitro selection
Because
there are no known naturally occurring deoxyribozymes, most known
deoxyribozyme sequences have been discovered through a high-throughput in vitro selection technique, similar to SELEX.
in vitro selection utilizes a "pool" of a large number of random DNA sequences (typically 1014–1015 unique strands) that can be screened for a specific catalytic activity. The pool is synthesized through solid phase synthesis such that each strand has two constant regions (primer
binding sites for PCR amplification) flanking a random region of a
certain length, typically 25–50 bases long. Thus the total number of
unique strands, called the sequence space, is 4N where N denotes the number of bases in the random region. Because 425 ≈ 1015,
there is no practical reason to choose random regions of less than 25
bases in length, while going above this number of bases means that the
total sequence space cannot be surveyed. However, since there are likely
many potential candidates for a given catalytic reaction within the
sequence space, random regions of 50 and even higher have successfully
yielded catalytic deoxyribozymes.
The pool is first subjected to a selection step, during which the
catalytic strands are separated from the non-catalytic strands. The
exact separation method will depend on the reaction being catalyzed. As
an example, the separation step for ribonucleotide cleavage often
utilizes affinity chromatography, in which a biological tag
attached to each DNA strand is removed from any catalytically active
strands via cleavage of a ribonucleotide base. This allows the catalytic
strands to be separated by a column that specifically binds the tag,
since the non-active strands will remain bound to the column while the
active strands (which no longer possess the tag) flow through. A common
set-up for this is a biotin tag with a streptavidin affinity column. Gel electrophoresis
based separation can also be used in which the change in molecular
weight of strands upon the cleavage reaction is enough to cause a shift
in the location of the reactive strands on the gel. After the selection step, the reactive pool is amplified via polymerase chain reaction
(PCR) to regenerate and amplify the reactive strands, and the process
is repeated until a pool of sufficient reactivity is obtained. Multiple
rounds of selection are required because some non-catalytic strands will
inevitably make it through any single selection step. Usually 4–10
rounds are required for unambiguous catalytic activity,
though more rounds are often necessary for more stringent catalytic
conditions. After a sufficient number of rounds, the final pool is
sequenced and the individual strands are tested for their catalytic
activity. The dynamics of the pool can be described through mathematical modeling
, which shows how oligonucleotides undergo competitive binding with the
targets and how the evolutionary outcome can be improved through fine
tuning of parameters.
Deoxyribozymes obtained through in vitro selection will be optimized for the conditions during the selection, such as salt concentration, pH, and the presence of cofactors.
Because of this, catalytic activity only in the presence of specific
cofactors or other conditions can be achieved using positive selection
steps, as well as negative selection steps against other undesired
conditions.
in vitro evolution
A similar method of obtaining new deoxyribozymes is through in vitro evolution. Though this term is often used interchangeably with in vitro selection, in vitro
evolution more appropriately refers to a slightly different procedure
in which the initial oligonucleotide pool is genetically altered over
subsequent rounds through genetic recombination or through point mutations. For point mutations, the pool can be amplified using error-prone PCR to produce many different strands of various random, single mutations. As with in vitro
selection, the evolved strands with increased activity will tend to
dominate the pool after multiple selection steps, and once a sufficient
catalytic activity is reached, the pool can be sequenced to identify the
most active strands.
The initial pool for in vitro evolution can be derived from a narrowed subset of sequence space, such as a certain round of an in vitro selection experiment, which is sometimes also called in vitro reselection.
The initial pool can also be derived from amplification of a single
oligonucleotide strand. As an example of the latter, a recent study
showed that a functional deoxyribozyme can be selected through in vitro evolution of a non-catalytic oligonucleotide precursor strand. An arbitrarily chosen DNA fragment derived from the mRNA transcript of bovine serum albumin was evolved through random point mutations over 25 rounds of selection. Through deep sequencing
analysis of various pool generations, the evolution of the most
catalytic deoxyribozyme strand could be tracked through each subsequent
single mutation.
This first successful evolution of catalytic DNA from a non-catalytic precursor could provide support for the RNA World hypothesis. In another recent study, an RNA ligase ribozyme was converted into a deoxyribozyme through in vitro
evolution of the inactive deoxyribo-analog of the ribozyme. The new RNA
ligase deoxyribozyme contained just twelve point mutations, two of
which had no effect on activity, and had a catalytic efficiency
of approximately 1/10 of the original ribozyme, though the researches
hypothesized that the activity could be further increased through
further selection.
This first evidence for transfer of function between different nucleic acids could provide support for various pre-RNA World hypotheses.
"True" catalysis?
Because most deoxyribozymes suffer from product inhibition and thus exhibit single-turnover
behavior, it is sometimes argued that deoxyribozymes do not exhibit
"true" catalytic behavior since they cannot undergo multiple-turnover
catalysis like most biological enzymes. However, the general definition of a catalyst requires only that the substance speeds up the rate of a chemical reaction
without being consumed by the reaction (i.e. it is not permanently
chemically altered and can be recycled). Thus, by this definition,
single-turnover deoxyribozymes are indeed catalysts. Furthermore, many endogenous enzymes (both proteins and ribozymes) also exhibit single-turnover behavior,
and so the exclusion of deoxyribozymes from the rank of "catalyst"
simply because it does not feature multiple-turnover behavior seems
unjustified.
Applications
Although RNA enzymes were discovered before DNA enzymes, the latter have some distinct advantages. DNA is more cost-effective, and DNA can be made with longer sequence length and can be made with higher purity in solid-phase synthesis. Several studies have shown the usage of DNAzymes to inhibit influenza A and B virus replication in host cells. Other studies show the usage of DNAzymes against human rhinovirus 14 and HCV
Drug clinical trials
Asthma
is characterized by eosinophil-induced inflammation motivated by a type
2 helper T cell (Th2). By targeting the transcription factor, GATA3, of
the Th2 pathway, with DNAzyme it may be possible to negate the
inflammation. The safety and efficacy of SB010, a novel 10-23 DNAzyme
was evaluated, and found to have the ability to cleave and inactivate
GATA3 messenger RNA in phase IIa clinical trials. Treatment with SB010
significantly offset both late and early asthmatic responses after
allergen aggravation in male patients with allergic asthma.
The transcription factor GATA-3 is also an interesting target, of the
DNAzyme topical formulation SB012, for a novel therapeutic strategy in ulcerative colitis
(UC). UC is an idiopathic inflammatory bowel diseases defined by
chronically relapsing inflammations of the gastrointestinal tract, and
characterized by a superficial, continuous mucosal inflammation, which
predominantly affects the large intestine. Patients that do not
effectively respond to current UC treatment strategies exhibit serious
drawbacks one of which may lead to colorectal surgery, and can result in
a severely compromised quality of life. Thus, patients with moderate or
severe UC may significantly benefit from these new therapeutic
alternatives, of which SB012 is in phase I clinical trials.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder, in which
patients suffer from eczema, often severe pruritus on the affected
skin, as well as complications and secondary infections. AD surfaces
from an upregulation of Th2-modified immune responses, therefore a novel
AD approach using DNAzymes targeting GATA-3 is a plausible treatment
option. The topical DNAzyme SB011 is currently in phase II clinical
trials.
DNAzyme research for the treatment of cancer is also underway. The
development of a 10-23 DNAzyme that can block the expression of IGF-I
(Insulin-like growth factor I, a contributor to normal cell growth as
well as tumorigenesis) by targeting its mRNA could be useful for
blocking the secretion of IGF-I from prostate storm primary cells
ultimately inhibiting prostate tumor development. Additionally, with
this treatment it is expected that hepatic metastasis would also be
inhibited, via the inhibition of IGF-I in the liver (the major source of
serum IGF-I).
Sensors
DNAzymes have found practical use in metal biosensors. A DNAzyme based biosensor for lead ion was used to detect lead ion in water in St. Paul Public Schools in Minnesota.
Asymmetric synthesis
Chirality is another property that a DNAzyme can exploit. DNA occurs in nature as a right-handed double helix and in asymmetric synthesis
a chiral catalyst is a valuable tool in the synthesis of chiral
molecules from an achiral source. In one application an artificial DNA
catalyst was prepared by attaching a copper ion to it through a spacer. The copper - DNA complex catalysed a Diels-Alder reaction in water between cyclopentadiene and an aza chalcone. The reaction products (endo and exo) were found to be present in an enantiomeric excess
of 50%. Later it was found that an enantiomeric excess of 99% could be
induced, and that both the rate and the enantioselectivity were related
to the DNA sequence.
Other uses
Other uses of DNA in chemistry are in DNA-templated synthesis, Enantioselective catalysis, DNA nanowires and DNA computing.